Medpace Holdings, Inc.

NasdaqGS MEDP

Medpace Holdings, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 28.13

Medpace Holdings, Inc. Price to Earnings Ratio (P/E) is 28.13 on January 14, 2025, a -10.17% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Medpace Holdings, Inc. 52-week high Price to Earnings Ratio (P/E) is 45.16 on March 21, 2024, which is 60.50% above the current Price to Earnings Ratio (P/E).
Medpace Holdings, Inc. 52-week low Price to Earnings Ratio (P/E) is 26.27 on November 18, 2024, which is -6.64% below the current Price to Earnings Ratio (P/E).
Medpace Holdings, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 35.15.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO	Dr. August James Troendle M.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	5375 Medpace Way
Employees	5,900
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Key trends

Past 5 years